MedTrace Logo

Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy

NCT06607796 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2024-09-25

No results posted yet for this study

Summary

The aim of this study was to evaluate the efficacy and safety of intratumoral injection of toluenesulfonamide(PTS) in combination with or without first-line chemoimmunization based on standard treatment for stage IV driver gene-negative non-small cell lung cancer.

Conditions

Interventions

DRUG

Toluenesulfonamide (PTS) Intratumoral Injection

intratumoral injection of toluenesulfonamide(PTS) to oligo lesions

Sponsors & Collaborators

  • Zhou Chengzhi

    lead OTHER

Principal Investigators

  • Chengzhi Zhou, doctor · The First Affiliated Hospital of Guangzhou Medical University,Guangzhou

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06607796 on ClinicalTrials.gov